RecruitingNot ApplicableNCT04271878

Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome


Sponsor

University of Calgary

Enrollment

26 participants

Start Date

Feb 2, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation. The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when upright/standing. The investigators are also searching for the ideal CO2 concentration to achieve the most effective response


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying RespirAct™ system (Thornhill Research Inc., Toronto, Canada) for people with orthostatic intolerance and postural tachycardia syndrome. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRespirAct™ system (Thornhill Research Inc., Toronto, Canada)

1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied) 2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels 3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg ) 4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg) 5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied 6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels.


Locations(1)

University of Calgary

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04271878


Related Trials